Technology transfer of behavioral economic tasks for assessing alcohol reinforcer pathology: Development and feasibility of a commercially-available tool for clinical practice

用于评估酒精强化病理学的行为经济任务的技术转让：用于临床实践的商用工具的开发和可行性

• 批准号: 10325335
• 负责人: Sarah Emily Snider
• 金额: $ 82.92万
• 依托单位: BEAM DIAGNOSTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-20 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10325335
• 关键词: Adoption; Alcohol consumption; Alcohols; American; Benchmarking; COVID-19 pandemic; Caring; Cause of Death; Censuses; Characteristics; Clinic; Clinical; Clinical Research; Clinical assessments; Computerized Medical Record; Data; Data Set; Decision Making; Development; Diagnostic; Distress; Education; Ensure; Environment; Feedback; Goals; Guidelines; Health Insurance Portability and Accountability Act; Healthcare; Healthcare Systems; Impairment; Individual; Internet; Language; Literature; Manuals; Measurement; Measures; Medical; Modeling; Modification; Morbidity - disease rate; Outpatients; Output; Pathology; Patients; Phase; Play; Prevalence; Process; Provider; Psychiatry; Public Health; Reporting; Rewards; Risk; Role; Sampling; Screening procedure; Secure; Security; Site; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Standardization; Stigmatization; System; Tablets; Technology Transfer; Testing; Translating; Translations; United States; Validation; acceptability and feasibility; alcohol misuse; alcohol reinforcement; alcohol screening; alcohol use disorder; base; behavioral economics; clinical application; clinical development; clinical practice; combat; digital; disability; discounting; disorder risk; drinking behavior; experience; health care disparity; implementation outcomes; improved; mortality; preventable death; prototype; reinforcer; routine practice; rural area; screening; tool; usability; web app

PROJECT SUMMARY Alcohol use disorder (AUD) contributes to excessive disability, morbidity, and mortality in the United States. As one of the nation’s leading causes of death, public health guidelines recommend consistent standardized alcohol screening. However, screening for alcohol misuse is underperformed, laborious, and is susceptible to demand characteristics and concerns about stigmatizing the patient. To combat these issues, BEAM Diagnostics, Inc. developed Beacon, a commercializable alcohol misuse digital screening tool based on the theoretical framework of reinforcer pathology dedicated to increasing standardized screening without stigmatizing the patient. In Phase I of this project, we conducted a clinical study at a large multi-site healthcare system serving approximately 1M patients per year and validated Beacon as demonstrating robust predictive accuracy of alcohol misuse and positive reports of feasibility and acceptability from providers. The goal of this Phase II SBIR is to finalize Beacon’s development into a fully realized commercial product, both as a stand-alone tool and as an integrated tool within an electronic medical record (EMR) system. Aim 1 will iterate and optimize the user-experience and accessibility of Beacon as a product, develop nationally representative norming, produce comprehensive clinical reference materials, ensure offline capability, and Spanish-language translation. Aim 2 will be dedicated to integrating Beacon into EPIC, a widely used electronic medical record system within a healthsystem partner, to improve usability, workflow capabilities, and record-keeping of alcohol misuse directly into a patient’s medical chart. In addition, Aim 2 will launch a wave-style education and implementation initiative to promote Beacon’s use in three outpatient departments. Finally, BEAM will complete an Exploratory Aim seeking to validate Beacon as a measurement-based care tool. At the conclusion of this Phase II project, BEAM will brought Beacon to market as a digital screening app for AUD, both as a stand-alone product and an EMR-integrated version.

项目摘要 在美国，酒精使用障碍（AUD）导致过度残疾，发病率和死亡率。作为 作为美国主要的死亡原因之一，公共卫生指南建议持续的标准化酒精 筛选然而，酒精滥用的筛查表现不佳，费力，并且容易受到需求的影响 特征和对患者污名化的担忧。为了解决这些问题，BEAM Diagnostics，Inc. 开发了Beacon，这是一种基于理论框架的可商业化的酒精滥用数字筛选工具 致力于增加标准化筛查而不使患者蒙受耻辱。同相 在该项目的第一部分，我们在一个大型多站点医疗保健系统中进行了一项临床研究， 患者，并验证了Beacon对酒精滥用的可靠预测准确性， 供应商对可行性和可接受性的积极报告。第二阶段SBIR的目标是最终确定 Beacon的发展成为一个完全实现的商业产品，既作为一个独立的工具，也作为一个集成的 电子病历（EMR）系统中的一个工具。目标1将优化和优化用户体验， Beacon作为产品的可访问性，开发具有全国代表性的规范，生产全面的临床 参考资料，确保离线能力和西班牙语翻译。目标2将致力于 将Beacon集成到EPIC中，EPIC是卫生系统合作伙伴中广泛使用的电子病历系统， 改进可用性、工作流程能力以及将酒精滥用记录直接保存到患者医疗记录中 图.此外，Aim 2将推出波浪式教育和实施举措，以促进Beacon的 在三个门诊部使用。最后，BEAM将完成探索性目标，以验证Beacon as a measurement-based测量care护理tool工具.在第二阶段项目结束时，BEAM将把Beacon带到 作为AUD的数字筛选应用程序，作为独立产品和EMR集成版本。